Interview: Head Of Turkish Industry Body Highlights Key Challenges In 2019
Executive Summary
Production localization and the fixed rate set for the euro against the lira will be key topics for the pharma industry in Turkey this year, with the expected further devaluation of the domestic currency likely to inflict more damage on companies. Turgut Tokgöz, secretary general of the Turkish industry association, spoke to Scrip.
You may also be interested in...
Localization Barriers To Trade In Medicines And Health Care Products: The Tricky Business Of Balancing Competing Interests
There is a clear tension at a global level between the need for the international movement of pharmaceutical products and the need for access to affordable medicines to support a sustainable health care system. Lincoln Tsang examines the global environment and suggests it is something that the British medicines and health care products industries will need to bear in mind when considering the prospect of the UK leaving the EU under WTO terms, as some are advocating.
Turkey’s New Fixed Euro Rate Spells More Pressure For Industry
The Turkish government has set the fixed Euro rate to calculate drug prices at TRY3.40 for 2019.
Political Turmoil, Big Pharma Resistance Threaten Turkey's Drug Production Drive
The Turkish government's drive to increase domestic production of medicines used the country has had some success for generic drugs, but it looks like the authorities may have given up hope when it comes to high-value products.